Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2927MR)

This product GTTS-WQ2927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2927MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15090MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ13646MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ6286MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ5301MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ9937MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ11508MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ4370MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ14705MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SEG101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW